Ready for the next cancer

Last finished cycle

Pancreatic ductal adenocarcinoma

[KNOWN] PDAC has poor survival, dense cancer-associated stroma, limited baseline T-cell infiltration, and frequent KRAS pathway dependence. [KNOWN] The evidence pack supports personalized RNA neoantigen vaccination as an active research direction but provides no validated target list or trial readouts. [INFERRED] The most testable portfolio should combine established cytotoxic backbones with genotype-selected KRAS strategies, immune priming, and deliberately risky stromal or immunotherapy hypotheses.